Description
Orforglipron (LY3502970) is a synthetic small-molecule non-peptide GLP-1 receptor agonist developed by Eli Lilly that activates GLP-1R through allosteric binding to the receptor’s orthosteric pocket, recapitulating Gs-coupled cAMP signaling downstream of GLP-1R activation. Unlike peptide-based GLP-1 receptor agonists such as semaglutide that require injection and absorption enhancers for oral delivery, Orforglipron is a non-peptide small molecule with intrinsic oral bioavailability. Researchers studying Class B GPCR pharmacology, non-peptide GLP-1R agonist binding, and comparative incretin receptor signaling use it as a defined small-molecule reference compound for the GLP-1R orthosteric pocket.
Storage and Handling
Store in a cool, dry place away from heat, moisture, and direct light. Keep container tightly sealed when not in use. Orforglipron is stable under standard ambient storage conditions; refer to the lot-specific certificate of analysis for specific requirements.
Compliance Notice
Orforglipron capsules are for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
